Full Product Name
NYX siRNA (Human)
Product Synonym Names
CLRP; Nyctalopin
Product Gene Name
NYX sirna
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for Q9GZU5
Specificity
NYX siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Purity/Purification
> 97%
Form/Format
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human NYX gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of NYX sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
NYX sirna
siRNA to inhibit NYX expression using RNA interference
Applications Tested/Suitable for NYX sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for NYX. It may not necessarily be applicable to this product.
NCBI Accession #
NP_072089.1
[Other Products]
NCBI GenBank Nucleotide #
NM_022567.2
[Other Products]
UniProt Primary Accession #
Q9GZU5
[Other Products]
UniProt Secondary Accession #
Q2M1S4; Q5H983; Q9H4J0; D3DWC0[Other Products]
UniProt Related Accession #
Q9GZU5[Other Products]
Molecular Weight
52,000 Da
NCBI Official Full Name
nyctalopin
NCBI Official Synonym Full Names
nyctalopin
NCBI Official Symbol
NYX [Similar Products]
NCBI Official Synonym Symbols
CLRP; NBM1; CSNB1; CSNB4; CSNB1A
[Similar Products]
NCBI Protein Information
nyctalopin
UniProt Protein Name
Nyctalopin
Protein Family
Nyctalopin
UniProt Gene Name
NYX [Similar Products]
UniProt Synonym Gene Names
CLRP [Similar Products]
UniProt Entry Name
NYX_HUMAN
NCBI Summary for NYX
The product of this gene belongs to the small leucine-rich proteoglycan (SLRP) family of proteins. Defects in this gene are the cause of congenital stationary night blindness type 1 (CSNB1), also called X-linked congenital stationary night blindness (XLCSNB). CSNB1 is a rare inherited retinal disorder characterized by impaired scotopic vision, myopia, hyperopia, nystagmus and reduced visual acuity. The role of other SLRP proteins suggests that mutations in this gene disrupt developing retinal interconnections involving the ON-bipolar cells, leading to the visual losses seen in patients with complete CSNB. [provided by RefSeq, Oct 2008]
UniProt Comments for NYX
NYX: Defects in NYX are the cause of congenital stationary night blindness type 1A (CSNB1A); also called X- linked congenital stationary night blindness (XLCSNB). Congenital stationary night blindness is a non-progressive retinal disorder characterized by impaired night vision. CSNB1A is characterized by impaired scotopic vision, myopia, hyperopia, nystagmus and reduced visual acuity. Belongs to the small leucine-rich proteoglycan (SLRP) family. SLRP class IV subfamily.
Protein type: Secreted; Secreted, signal peptide
Chromosomal Location of Human Ortholog: Xp11.4
Cellular Component: proteinaceous extracellular matrix; intracellular
Biological Process: visual perception; response to stimulus
Disease: Night Blindness, Congenital Stationary, Type 1a
Research Articles on NYX
1. Loss of ERG amplitude and apparent ON-pathway dysfunction at high temporal frequencies distinguish this patient with a Trp237Ter NYX mutation from those with other previously reported NYX mutations.
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
